These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3258764)

  • 1. [Experimental parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine].
    Kryzhanovskiĭ GN; Atadzhanov MA; Zagorevskiĭ VA; Sharkova LM; Voronina TA
    Biull Eksp Biol Med; 1988 Apr; 105(4):397-401. PubMed ID: 3258764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lipid peroxidation in the caudate nuclei in experimental parkinsonian syndrome].
    Kucherianu VG; Atadzhanov MA; Nikushkin EV; Zagorevskiĭ VA; Sharkova LM
    Biull Eksp Biol Med; 1989 Jan; 107(1):39-41. PubMed ID: 2783652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MPTP in animal models of Parkinson's disease.
    Kopin IJ; Schoenberg DG
    Mt Sinai J Med; 1988 Jan; 55(1):43-9. PubMed ID: 3126391
    [No Abstract]   [Full Text] [Related]  

  • 6. [Experimental model of Parkinson disease induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Renkawek K
    Neuropatol Pol; 1986; 24(1):1-8. PubMed ID: 3489205
    [No Abstract]   [Full Text] [Related]  

  • 7. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.
    Chiueh CC; Markey SP; Burns RS; Johannessen JN; Jacobowitz DM; Kopin IJ
    Psychopharmacol Bull; 1984; 20(3):548-53. PubMed ID: 6332333
    [No Abstract]   [Full Text] [Related]  

  • 8. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of amiridin on the MPTP-induced Parkinson-like syndrome in monkeys].
    Burov IuV; Metkalova SE; Kustov AE; Petrov GV; Shul'govskiĭ VV
    Biull Eksp Biol Med; 1992 Nov; 114(11):495-7, 494. PubMed ID: 1290822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of sleep-wakefulness structure in parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and oxotremorine].
    Gugutsidze DA; Nerobkova LN; Boronina TA
    Biull Eksp Biol Med; 1989 Aug; 108(8):206-9. PubMed ID: 2804326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP.
    Chen SD; Xu DL; Yu HZ; Tang QM; Xu XR; Wang ZG; Liang PF
    Chin Med J (Engl); 1988 Dec; 101(12):879-83. PubMed ID: 3150735
    [No Abstract]   [Full Text] [Related]  

  • 12. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): one designer drug and serendipity.
    Weingarten HL
    J Forensic Sci; 1988 Mar; 33(2):588-95. PubMed ID: 3259617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK; Mehta AK; Aley KO; Shukla VK
    Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985.
    J Neural Transm Suppl; 1986; 20():1-81. PubMed ID: 3489069
    [No Abstract]   [Full Text] [Related]  

  • 15. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
    Kopin IJ
    Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of difenin on experimental parkinsonian syndrome].
    Kryzhanovskiĭ GN; Atadzhanov MA; Kucherianu VG
    Biull Eksp Biol Med; 1990 Sep; 110(9):242-4. PubMed ID: 2268704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [MPTP and Parkinson's disease].
    Imai H
    No To Shinkei; 1988 Nov; 40(11):1011-24. PubMed ID: 3064783
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of substance P on experimental parkinsonian syndrome].
    Kryzhanovskiĭ GN; Atadzhanov MA; Kucherianu VG
    Biull Eksp Biol Med; 1989 Oct; 108(10):404-7. PubMed ID: 2480824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
    Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D
    Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
    [No Abstract]   [Full Text] [Related]  

  • 20. FGF-2 in the MPTP model of Parkinson's disease: effects on astroglial cells.
    Otto D; Unsicker K
    Glia; 1994 May; 11(1):47-56. PubMed ID: 8070894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.